MY175351A - Method and kit for measurement of nk cell activity - Google Patents

Method and kit for measurement of nk cell activity

Info

Publication number
MY175351A
MY175351A MYPI2013002917A MYPI2013002917A MY175351A MY 175351 A MY175351 A MY 175351A MY PI2013002917 A MYPI2013002917 A MY PI2013002917A MY PI2013002917 A MYPI2013002917 A MY PI2013002917A MY 175351 A MY175351 A MY 175351A
Authority
MY
Malaysia
Prior art keywords
measurement
cell activity
kit
cancer
incidence
Prior art date
Application number
MYPI2013002917A
Other languages
English (en)
Inventor
Jae Myun Lee
Joo Chun Yoon
Sang Woo Park
Jong Sun Kim
Original Assignee
Atgen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atgen Co Ltd filed Critical Atgen Co Ltd
Publication of MY175351A publication Critical patent/MY175351A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
MYPI2013002917A 2011-02-14 2012-02-10 Method and kit for measurement of nk cell activity MY175351A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020110012983A KR20120093002A (ko) 2011-02-14 2011-02-14 Nk 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트

Publications (1)

Publication Number Publication Date
MY175351A true MY175351A (en) 2020-06-22

Family

ID=46672988

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2013002917A MY175351A (en) 2011-02-14 2012-02-10 Method and kit for measurement of nk cell activity

Country Status (20)

Country Link
US (2) US11442069B2 (cg-RX-API-DMAC7.html)
EP (1) EP2676139B1 (cg-RX-API-DMAC7.html)
JP (5) JP6629497B2 (cg-RX-API-DMAC7.html)
KR (3) KR20120093002A (cg-RX-API-DMAC7.html)
CN (1) CN103370622B (cg-RX-API-DMAC7.html)
AU (2) AU2012219184A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013020454B1 (cg-RX-API-DMAC7.html)
CA (1) CA2826053C (cg-RX-API-DMAC7.html)
CL (1) CL2013002361A1 (cg-RX-API-DMAC7.html)
DK (1) DK2676139T3 (cg-RX-API-DMAC7.html)
EA (1) EA038959B1 (cg-RX-API-DMAC7.html)
ES (1) ES2797549T3 (cg-RX-API-DMAC7.html)
IL (1) IL227952B (cg-RX-API-DMAC7.html)
MX (1) MX361731B (cg-RX-API-DMAC7.html)
MY (1) MY175351A (cg-RX-API-DMAC7.html)
RU (1) RU2635194C2 (cg-RX-API-DMAC7.html)
SG (1) SG192247A1 (cg-RX-API-DMAC7.html)
TW (2) TWI668445B (cg-RX-API-DMAC7.html)
UA (1) UA120697C2 (cg-RX-API-DMAC7.html)
WO (1) WO2012110878A2 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Nk 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
KR101520534B1 (ko) 2012-05-07 2015-05-21 고려대학교 산학협력단 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법
EP3066474B1 (en) 2013-11-05 2019-04-03 Agency For Science, Technology And Research Bladder carcinoma biomarkers
JP6073417B2 (ja) * 2015-06-26 2017-02-01 チャ バイオテック カンパニー リミテッド 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
KR101926166B1 (ko) * 2016-05-24 2018-12-06 재단법인 아산사회복지재단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
WO2017204446A2 (ko) * 2016-05-24 2017-11-30 울산대학교 산학협력단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
CN107686828A (zh) * 2016-08-04 2018-02-13 英普乐孚生物技术(上海)有限公司 一种nk细胞无血清培养基
CN106085958A (zh) * 2016-08-04 2016-11-09 英普乐孚生物技术(上海)有限公司 一种nk细胞的制备方法
CN106222140A (zh) * 2016-08-04 2016-12-14 英普乐孚生物技术(上海)有限公司 一种nk细胞无血清培养基及其配制方法
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル-マイヤーズ スクイブ カンパニー アルファ-シヌクレインに対する抗体およびその使用
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
KR102090698B1 (ko) * 2017-08-24 2020-04-23 연세대학교 산학협력단 암의 진단, 모니터링, 또는 예후 예측을 위해 생체 외 인터페론-감마의 양을 측정하는 방법
CN115710576A (zh) 2018-02-01 2023-02-24 Nkmax有限公司 产生天然杀伤细胞的方法和用于治疗癌症的组合物
WO2020168250A1 (en) * 2019-02-14 2020-08-20 Research Institute At Nationwide Children's Hospital Use of a stimulating agent to assay immune cell potency
CN114615886A (zh) * 2019-08-29 2022-06-10 得克萨斯大学体系董事会 细胞冷冻保存培养基
CA3153542A1 (en) * 2019-09-25 2021-04-01 Leto Laboratories Co., Ltd Recombinant interleukin-15 analog
EP4048296A4 (en) * 2019-11-29 2024-01-24 Nkmax Co., Ltd. Method of producing natural killer cells and compositions thereof
JP7849854B2 (ja) * 2020-07-29 2026-04-22 国立大学法人東北大学 シヌクレイノパチーを予防又は治療するために使用されるペプチド
CN113533729B (zh) * 2021-06-15 2024-09-06 北京大学人民医院 一种鉴定aml患者骨髓中nk细胞耗竭的研究方法及其应用
KR20240117150A (ko) * 2021-12-17 2024-07-31 유니버시티 오브 켄트 재조합 생물학적 분자의 생산을 위한 서열 및 방법
KR20230156518A (ko) 2022-05-06 2023-11-14 (주)다이오진 엑소좀 내의 인터페론 감마 유전자 측정을 이용한 암 조기 진단 방법 및 진단 키트
CN115247149B (zh) * 2022-08-22 2023-06-16 华域生物科技(天津)有限公司 适用于nk细胞的培养基组合物及培养方法
CN115855779A (zh) * 2023-01-18 2023-03-28 山东康华生物医疗科技股份有限公司 一种定量检测nk细胞活性的磁微粒化学发光试剂盒及其检测方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2635088A (en) 1987-12-04 1989-06-08 Du Pont Merck Pharmaceutical Company, The Immobilized interleukin 2 and interleukin 2 containing a carboxyl-terminal extension
CA2168584C (en) * 1993-08-09 2008-10-14 Edward Baral A method for sensitization of cancer cells for killer cell mediated lysis
JP2000510813A (ja) * 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Il−12用処方
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
JP3995248B2 (ja) 2001-08-13 2007-10-24 準二郎 土山 エプスタインバーウイルス陰性のnk細胞株
AU2002321931A1 (en) * 2001-11-20 2003-06-10 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
WO2003082206A2 (en) * 2002-03-26 2003-10-09 Centocor, Inc. Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses
JP2004305095A (ja) 2003-04-07 2004-11-04 Limuloid Science Kk 細胞活性化検出方法
CN1297567C (zh) * 2003-06-13 2007-01-31 马菁 具有抗肿瘤功能的双功能融合蛋白及其制备方法和应用
ES2356154T3 (es) * 2003-07-21 2011-04-05 Transgene S.A. Citoquinas multifuncionales.
WO2005013950A2 (en) 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
SG148161A1 (en) 2003-11-05 2008-12-31 Palingen Inc Enhanced b cell cytotoxicity of cdim binding antibody
KR100565764B1 (ko) 2005-05-02 2006-03-28 (주)에이티젠 환경 스트레스에 내성을 부여하는 신규한 펩타이드 및 이를포함하는 융합 단백질
US20050203010A1 (en) 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
JP4653465B2 (ja) 2004-10-25 2011-03-16 泰信 小林 ナチュラルキラー細胞の増殖促進方法およびそれに用いる培養組成物
WO2006110577A2 (en) * 2005-04-08 2006-10-19 Morningside Venture Investments Limited Use of fril proteins for reducing the production of pro-inflammatory cytokines
AU2007277050A1 (en) * 2006-07-28 2008-01-31 The Research Foundation Of State University Of New York Methods and kits for measurement of lymphocyte function
WO2008070647A1 (en) * 2006-12-07 2008-06-12 Wyeth Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample
AU2008204433B2 (en) 2007-01-11 2014-03-13 Novo Nordisk A/S Anti-KIR antibodies, formulations, and uses thereof
EP2048237A1 (en) 2007-10-05 2009-04-15 Avir Green Hills Biotechnology Research Development Trade Ag Replication deficient Influenza virus for the expression of heterologous sequences
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Nk 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트

Also Published As

Publication number Publication date
MX2013009380A (es) 2013-12-16
CL2013002361A1 (es) 2014-06-27
JP2017129597A (ja) 2017-07-27
JP2014510517A (ja) 2014-05-01
EA038959B1 (ru) 2021-11-15
JP6798922B2 (ja) 2020-12-09
AU2017202628B2 (en) 2019-08-22
IL227952A0 (en) 2013-09-30
TWI668445B (zh) 2019-08-11
JP2019207242A (ja) 2019-12-05
IL227952B (en) 2019-01-31
JP2022043119A (ja) 2022-03-15
EP2676139A2 (en) 2013-12-25
EP2676139A4 (en) 2014-12-03
KR20130136012A (ko) 2013-12-11
CA2826053C (en) 2021-05-25
NZ614345A (en) 2015-09-25
CN103370622A (zh) 2013-10-23
WO2012110878A2 (en) 2012-08-23
BR112013020454B1 (pt) 2023-03-21
CN103370622B (zh) 2018-02-13
RU2013141487A (ru) 2015-03-27
BR112013020454A2 (pt) 2016-10-18
ES2797549T3 (es) 2020-12-02
UA120697C2 (uk) 2020-01-27
AU2012219184A1 (en) 2013-09-05
CA2826053A1 (en) 2012-08-23
SG192247A1 (en) 2013-09-30
KR20120093002A (ko) 2012-08-22
TWI681191B (zh) 2020-01-01
US20140017713A1 (en) 2014-01-16
JP7660605B2 (ja) 2025-04-11
US11442069B2 (en) 2022-09-13
JP2023115006A (ja) 2023-08-18
DK2676139T3 (da) 2020-06-15
US20220229070A1 (en) 2022-07-21
TW201245718A (en) 2012-11-16
BR112013020454A8 (pt) 2022-11-29
TW201741670A (zh) 2017-12-01
KR101438573B1 (ko) 2014-09-12
KR20130032410A (ko) 2013-04-01
NZ710432A (en) 2017-04-28
EA201391187A1 (ru) 2013-12-30
EP2676139B1 (en) 2020-05-06
RU2635194C2 (ru) 2017-11-09
AU2017202628A1 (en) 2017-05-11
JP6629497B2 (ja) 2020-01-15
US12379384B2 (en) 2025-08-05
WO2012110878A3 (en) 2013-01-31
KR101341538B1 (ko) 2013-12-18
MX361731B (es) 2018-12-14

Similar Documents

Publication Publication Date Title
WO2012110878A3 (en) Method of diagnosing cancer and diagnosis kit using measurement of nk cell activity
MX2013000917A (es) Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
FR2965360B1 (fr) Procede de diagnostic in situ de batteries par spectroscopie d'impedance electrochimique
MX382244B (es) Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales
EA201500080A1 (ru) Способ in vitro диагностирования и мониторинга рака
WO2012173976A3 (en) Methods and apparatus for assessing activity of an organ and uses thereof
MX2015012303A (es) Un metodo no invasivo para medir el estres oxidativoy daño oxidativo de los biomarcadores cutaneos.
MX358474B (es) Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson.
NZ608316A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2014053996A3 (en) Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs
MX381530B (es) Método in vitro para el diagnóstico de la enfermedad de niemann-pick.
WO2014087255A3 (en) Systems and methods for monitoring biological fluids
WO2011130647A3 (en) Compositions and methods for characterizing a myopathy
SI2544582T1 (sl) Postopek za elektrokemijsko merjenje koncentracije analita in vivo in gorivna celica zanj
WO2014169011A3 (en) Methods for treating immune diseases
WO2012008747A3 (ko) 피부 진단 방법 및 키트
WO2013167727A3 (en) Method for determining arthritis relapse risk
WO2012145399A3 (en) Methods of diagnosing cancer in a patient
GB201114909D0 (en) Biomarkers for lysosomal storage disorders
WO2013050950A3 (en) Method for monitoring, diagnosis and/or prognosis of hypoxia related disorders using nfat5
TH101590B (th) วิธีการในการวินิจฉัยโรคมะเร็งและชุดตรวจวินิจฉัยโดยการใช้การตรวจวัดฤทธิ์ของ nk เซลล์
GB201107557D0 (en) Method
WO2012024302A3 (en) Biomarkers of cancer
WO2011153590A8 (en) Use of interferon epsilon in methods of diagnosis and treatment
MX2011008057A (es) Biomarcador para el diagnostico de cancer de mama.